Literature DB >> 24942406

Relationship between serum cholesterol efflux capacity and glucose intolerance in Japanese-Americans.

Mitsunobu Kubota1, Shuhei Nakanishi, Masatoshi Hirano, Shusaku Maeda, Masayasu Yoneda, Tomokazu Awaya, Kiminori Yamane, Nobuoki Kohno.   

Abstract

AIM: Serum cholesterol efflux has been suggested to be a key anti-atherogenic function of reverse cholesterol transport. Meanwhile, the quantitative and qualitative alteration of the levels of lipoproteins in the serum has been reported in patients with diabetes, although it remains unclear whether the serum cholesterol efflux capacity is impaired in cases of newly diagnosed glucose intolerance. We thus assessed the relationship between the serum cholesterol efflux capacity and glucose intolerance as detected using oral glucose tolerance tests (OGTTs).
METHODS: We measured the capacity of whole serum to mediate cholesterol efflux from human THP-1 macrophages in a cohort of 439 Japanese-Americans who underwent 75-g OGTTs. A multiple regression analysis was performed to examine the relationship between the serum cholesterol efflux capacity and glucose intolerance.
RESULTS: The serum cholesterol efflux capacity was found to be negatively correlated with the area under the curve for the serum glucose concentration during the 75-g OGTTs in all subjects. In addition, the serum cholesterol efflux capacity was found to be modestly but significantly lower in the glucose intolerance group (31.4 ± 6.2%) than in the normal glucose tolerance group (33.2 ± 6.1%). There was also a negative association between the serum cholesterol efflux capacity and glucose intolerance after adjusting for age and sex. Moreover, this association remained significant even after further adjustments for serum total cholesterol, high-density lipoprotein cholesterol, apolipoprotein AI and C-reactive protein.
CONCLUSIONS: The serum cholesterol efflux capacity is impaired in Japanese-Americans newly diagnosed with glucose intolerance. This impairment may contribute in some manner to increasing the risk of atherosclerotic disease in subjects with glucose intolerance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24942406     DOI: 10.5551/jat.24315

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  6 in total

Review 1.  Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease.

Authors:  Rai Ajit K Srivastava
Journal:  Mol Cell Biochem       Date:  2017-08-21       Impact factor: 3.396

Review 2.  High-Density Lipoprotein Function Measurement in Human Studies: Focus on Cholesterol Efflux Capacity.

Authors:  Anand Rohatgi
Journal:  Prog Cardiovasc Dis       Date:  2015-05-09       Impact factor: 8.194

3.  High-density lipoprotein cholesterol efflux capacity is not associated with atherosclerosis and prevalence of cardiovascular outcome: The CODAM study.

Authors:  Tatjana Josefs; Kristiaan Wouters; Uwe J F Tietge; Wijtske Annema; Robin P F Dullaart; Tomas Vaisar; Ilja C W Arts; Carla J H van der Kallen; Coen D A Stehouwer; Casper G Schalkwijk; Ira J Goldberg; Edward A Fisher; Marleen M J van Greevenbroek
Journal:  J Clin Lipidol       Date:  2019-10-31       Impact factor: 4.766

Review 4.  Beneficial Effects of Adiponectin on Glucose and Lipid Metabolism and Atherosclerotic Progression: Mechanisms and Perspectives.

Authors:  Hidekatsu Yanai; Hiroshi Yoshida
Journal:  Int J Mol Sci       Date:  2019-03-08       Impact factor: 5.923

Review 5.  High Density Lipoproteins and Diabetes.

Authors:  Blake J Cochran; Kwok-Leung Ong; Bikash Manandhar; Kerry-Anne Rye
Journal:  Cells       Date:  2021-04-09       Impact factor: 6.600

6.  HDL cholesterol efflux normalised to apoA-I is associated with future development of type 2 diabetes: from the CORDIOPREV trial.

Authors:  Ruth Blanco-Rojo; Pablo Perez-Martinez; Javier Lopez-Moreno; Javier Martinez-Botas; Javier Delgado-Lista; Ben van-Ommen; Elena Yubero-Serrano; Antonio Camargo; Jose M Ordovas; Francisco Perez-Jimenez; Diego Gomez-Coronado; Jose Lopez-Miranda
Journal:  Sci Rep       Date:  2017-10-02       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.